Dental CariesPhase 3NCT07741409
Povidone Iodine for Caries Prevention
A Phase 3 study testing Povidone Iodine 5% Soln,Top,Kit and Probiotics in people with Dental Caries, run by Jeffrey A. Banas at 1 site in United States.
Trial summary
The goal of this clinical trial is to learn if Povidone Iodine works to prevent tooth decay and suppress the mouth germs responsible for tooth decay. The main questions it aims to answer are: 1. Read more about this study
- Who is it for?
- Ages 1 year to 3 yearsHealthy volunteers can take part
- Conditions the study is for
- Dental Caries
- What is being tested?
- Povidone Iodine 5% Soln,Top,Kit and Probiotics
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 174 participants
- Where
- 1 siteUnited States
- Study dates
- 3 Aug 2026to 30 Jun 2028
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 3 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- 1 to 3 years of age
- No plans to relocate in the next 12 months
Who cannot join
- Thyroid condition
- Antibiotic usage in the prior 3 months
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Iowa College of Dentistry
Iowa City, Iowa, 52242
Jeffrey A Banas, PhD, 319-335-9911, jeffrey-banas@uiowa.edu
Michael J Kanellis, DDS, 319-335-7439, michael-kanellis@uiowa.edu
About this study
Official title: Povidone Iodine to Prevent Early Childhood Caries
The goal of this clinical trial is to learn if Povidone Iodine works to prevent tooth decay and suppress the mouth germs responsible for tooth decay. The main questions it aims to answer are:
- How will home use of Povidone Iodine, as an adjunct treatment to standard dental care, reduce the incidence of tooth decay?
- How will home use of Povidone Iodine reduce the mouth germs responsible for tooth decay?
- If Povidone Iodine use is accompanied by probiotic use, will its effectiveness be even better than Povidone Iodine alone?
Read more
Participants will:
- Provide a plaque sample at the beginning of the study.
- Swab their children's teeth once a week for one month and then monthly thereafter. Some participants may be asked to use probiotic drops nightly after brushing their teeth.
- Keep a record of compliance.
- Return every 6 months for a dental exam and to provide a plaque sample. Keep a diary of their symptoms and the number of times they use a rescue inhaler
Read the detailed description
Dental 'caries' is the term used to describe dental decay or 'cavities'. Dental caries can occur at any age but lesions prior to a child's 6th birthday qualify as 'early childhood caries' (ECC) and possibly as 'severe' early childhood caries (SECC) if the onset and severity meet definitions put forth by the American Academy of Pediatric Dentistry. ECC and SECC can have several unfortunate downstream consequences: pain, infection, nutritional deficiencies, poorer concentration in school, and social/cosmetic/financial concerns. Recent epidemiologic trends in ECC/SECC, reported by Kotha et al. (2022) based on data from the National Health and Nutrition Examination Survey (NHANES), have found little change in prevalence over the span from 2013 to 2018 with approximately 20% of children experiencing ECC by age 3 years with over half that percentage categorized as having SECC. Thus, there remains a critical need to improve prevention and treatment strategies.
Many variables can affect the likelihood of developing dental decay but prominent among these are excess consumption of sugary foods and drinks, inadequate oral hygiene, and poor access to dental care and oral health educational resources. Ultimately, microbes on the surface of teeth convert dietary sugar to acid that dissolves enamel thereby initiating and advancing decay. Brushing regularly with fluoridated toothpaste helps suppress the microbial population which decreases the acid challenge while fluoride promotes remineralization of enamel. Seeing a dentist regularly can ensure that any decay that develops is treated at its earliest stages thereby saving teeth.
While prevention strategies work well for many individuals, for a multitude of potential reasons they may prove inadequate for others. In particular, children with poor access to professional care or who are disadvantaged in other respects frequently fail to realize the benefits of the current standard of care.
The objective of this investigation is to test the effectiveness of povidone iodine (PI) as a home-administered preventive or treatment for dental caries that, unlike other treatment options, addresses the underlying cause - dental plaque that has an overabundance of strong acid-producing bacterial species. This imbalance of strong acid producers is referred to as a 'dysbiosis'. We will also test whether combining PI with probiotics - living microbes that can be used to boost health - will have a greater benefit than PI alone in maintaining or restoring a healthy microbial composition to dental plaque. We are in a unique position to leverage our access to children at high risk for decay to test multiple integrated hypotheses that we predict will result in more effective home dental care, and significant reductions in the incidence and severity of dental decay that is longer lasting than is possible with the current standard of care.
Despite tremendous advances in understanding how particular microbes in dental plaque lead to tooth decay, prevention and treatment options remain non-specific - dedicated to plaque control rather than to replacing the offending microbes with health-related species (correcting the dysbiosis). This limitation results in the chronic presence of an elevated microbial risk that likely proves most consequential in individuals with limited access to professional care and suboptimal oral hygiene habits. Importantly, PI is unique among current standard of care options because there is evidence that it not only can prevent caries but that it also attacks the microbial offenders that drive caries development. The addition of fluoride to water supplies and oral health care products was a game-changer. Protection appears to be due to improving the enamel remineralization/demineralization balance rather than any antimicrobial activity despite in vitro evidence of selective toxicity against S. mutans.
Consequently, fluoride is excellent at caries prevention (when available/applied in adequate amounts and frequency) but does not improve a dysbiotic plaque microbiome. Chlorhexidine, sometimes prescribed for individuals with rampant caries, is considered the 'gold-standard' of anti-plaque agents but a large NIDCR-sponsored study (Papas et al., 2012) found no greater protection against caries than the use of fluoride alone.
Additionally, chlorhexidine use does not appear to remedy a cariogenic dysbiosis. Silver products have a long history in dental treatment and have generated renewed interest in recent years. The strong staining properties of silver, however, limit its application. The preponderance of evidence does not support a role for silver in improving a cariogenic microbial dysbiosis but further investigation is necessary.
Iodine, like silver, has long been recognized for its antiseptic/antimicrobial properties. Combining iodine with povidone improves water solubility. Evidence to date suggests that PI offers the greatest breadth of desirable properties but additional investigation is necessary in order to make a strong case for widespread adoption by clinicians. This proposal seeks to document the effectiveness of home use of PI for providing long-term reduction in caries risk by reducing the microbial dysbiosis within cariogenic dental plaque.
Hypothesis(es) and objective(s): We hypothesize that home use of PI will reduce the incidence and severity of dental decay in a high-risk population of children. Though not a substitute for proper oral hygiene such as brushing twice a day for two minutes each, its application is so quick that compliance is more likely than engaging in routine, effective oral hygiene and it would likely boost the effectiveness of imperfect oral hygiene practices. We further hypothesize that PI has selective toxicity for oral pathogens and its use would improve the microbial make-up of dental plaque thereby helping sustain beneficial effects. Finally, we hypothesize that this latter property of PI can be combined with probiotic administration to elevate the beneficial effect.
Study Protocol:
Patient Pool: The patient pool will be children of ages 1 to 3 years old who receive care
through the Infant Oral Health clinic that is part of the Iowa City Women, Infant, Children (WIC) Program in Iowa City. The University of Iowa Department of Pediatric Dentistry has an ongoing collaboration with the IC-WIC to provide oral health care and sees 16 to 24 children per week (Weber-Gasparoni et al., 2010). The children are typically from low-income families and all are at high risk for decay. We estimate that we could recruit 3 to 5 subjects/week. To estimate the number of subjects necessary to obtain statistically significant results, we extrapolated from the results of Lopez et al. (2002) who used 10% povidone iodine and an outcome measure of new caries. Based on the
differences between treatment and placebo groups, 126 subjects (42 Group 1, PI; 42 Group 2, PI + probiotics; and 42 Group 3, placebo) would give 80% power to determine a statistical difference in caries outcome with an alpha error of 0.05. To meet this number, we will enroll 174 subjects to account for an estimated 27% annual attrition.
Subjects will be randomly assigned to Groups 1, 2 or 3. However, if a subject consents to use PI but not probiotics, their assignment will be to either Group 1 or Group 3. We anticipate completing enrollment during year 1 of the study but have reserved 18 months to meet the recruitment goal. We also want to make clear that Group 3 will be the placebo group for the Group 1 iodine treatment. After considerable contemplation, we decided against including a strict placebo group for the probiotic administration. We considered having Group 3 use both the PI placebo and probiotic placebo but that would 'muddy' the analytical comparison with Group 1 (PI alone). Including another distinct placebo group would add considerable expense to the project that might not be justified if compliance with a daily regimen turned out to be low. As designed, we feel this project will yield strong data for the efficacy of home use of PI. The inclusion of a probiotic group has the potential to add significant insight into the mechanism by which PI exerts any observed benefit, or it may offer a lesson in the limits of compliance for any sort of daily oral health promoting regimen.
Enrollment and Visit Protocols: Pediatric Dental Residents will be the practitioners
treating the prospective participants. They will be calibrated with respect to caries scoring (ICDAS) prior to initiating the study. Once it is determined that the subjects satisfy the inclusion criteria (child of appropriate age; no imminent plans to relocate), they will follow an IRB-approved recruitment/enrollment protocol that will also determine
if any exclusion criteria (thyroid condition; antibiotic usage in the prior 3 months) apply. Once informed consent is obtained, the current caries status will be recorded and a pooled plaque sample will be taken using a sterile foam-tipped applicator (Puritan®) and swabbing all exposed tooth surfaces. The study coordinator will provide the practitioner with PI (Povi-One povidone iodine unit dose kit; Elevate Oral Care®), PI and probiotic drops (Prodentis by BioGaia), or placebo (colored tea for PI). The practitioner will apply the PI treatment onto the teeth of the participant and instruct them in home use. For participants given probiotic, verbal instructions will be provided to administer the drops once a day after brushing before bedtime. While this protocol precludes keeping practioners blinded with respect to the intervention, only the study coordinator will keep a record of the participants' group assignment so that practioners will not have access to group assignment records at follow-up appointments thereby minimizing the possibility of bias in subsequent caries evaluations. The PI protocol will be one application per week for one month and then once a month thereafter. Probiotic application will be daily. The concentration of the povidone iodine will be 5% and the maximum dose of probiotic will be 5 drops. The amount disbursed in an application and the frequency of application will be well within the safety margins for iodine exposure (Frank et al., 2020). Subjects will receive reminders ahead of a scheduled home application of PI via text message or communication method of choice to help ensure compliance. Subjects will also have the opportunity to reply to the messaging so that compliance can be tracked and/or keep a home diary of compliance and personal oral hygiene habits (How many times per day/week do the children brush? Themselves or by parents? Does the toothpaste contain fluoride?). At each 6-month follow-up
appointment, subjects will again have their caries status recorded and provide a pooled-plaque sample. They will also be asked questions related to use of antibiotics during the period between baseline and follow-up appointments. Maximal duration of participation for any subject will be 1 year.
Processing of Plaque Samples for Microbiome Analysis: Pooled plaque samples will be
collected as described above. The foam tip of the applicator will be broken off into 300ul RNAlater™ (Invitrogen) for transport to lab and isolation of DNA using the Qiagen DNeasy PowerLyzer PowerSoil Kit. The DNA that is recovered contains strands from all the microbes present in the sample. Technology allows the DNA to be sequenced and computational software is capable of analyzing the sequences and providing a breakdown of the proportional representation of the different types of microbes present. To accomplish this, the DNA samples will be sent to LC Sciences (Houston, TX) for the sequencing and microbial data analysis. [For those technically inclined, the 16S sequencing primers will target the V3 and V4 regions. The resulting 465bp amplicon will be sequenced on a NovaSeq platform with 250bp paired-end reads. Raw data files will be obtained in FASTQ format, overlapping sequences merged, screened for data quality and chimera filtered. The algorithm DADA2 will then be applied to generate representative sequences and construction of Amplicon Sequence Variant tables that will be the basis for analyses of diversity and differential abundance analyses.
Taxonomy will be assigned using the QIIME2 naïve bayes classifier (Bokulich et al., 2018) trained on the Human Oral Microbiome Database (HOMD) v15.23].
Previous studies have demonstrated that treatment with 10% PI can reduce salivary/plaque levels of the highly acidogenic bacterial species Streptococcus mutans (Amin et al., 2004; Simratvir et al., 2010) but further substantiation including effects on the totality of the oral microbial population are warranted. We recently completed a longitudinal study focusing on the microbial changes that preceded a diagnosis of ECC (unpublished data) and found that S. mutans appeared to be the main driver or major contributor in about three-quarters of the children. In the other 25% who developed caries, it appeared that non-mutans acidogenic species or the loss of base-producing species were the major drivers. Therefore, our microbiome analysis will focus on S. mutans as well as on changes in the representation of key genera that are health related (Neisseria, Haemophilus) or caries related (Actinomyces, Prevotella, Kingella, Candida).
Data Analyses: Our data analyses will focus on answering three main questions: 1) did
home use of PI reduce caries incidence and severity?; 2) did home use of PI reduce the presence in dental plaque of microbial species most associated with dental decay?; and 3) did a daily regimen of probiotics enhance the effectiveness of the PI treatments by further reducing caries incidence/severity and the presence of decay-associated microbes? To answer each of these questions, caries rates and microbial composition outcomes from Group 3 (placebo) will be compared with Groups 1 (PI) and 2 (PI + probiotic), individually and in combination. Outcomes from Groups 1 and 2 can also be compared directly. We expect to use ANOVA for statistical analysis but will consult with a biostatistician to ensure that all analyses are experimentally appropriate and valid.
The analyses described above will provide answers to our three main questions and directly address the hypotheses being tested. Our data on compliance will provide perspective for these outcomes. We anticipate that home use of PI is quick and simple enough to elicit good compliance. We are less sure of what to expect with the probiotic. On the one hand, administration (5 drops) is quicker than brushing one's teeth (though recommended use is after brushing). On the other hand, our study groups may not be particularly proficient in adhering to recommended oral hygiene practices. Overall, we expect the PI to be protective to a significant degree regardless of personal daily oral hygiene habits. However, we expect that the magnitude of protection will improve in direct proportion to the frequency of personal oral hygiene, including compliance of probiotic use.
- Conditions
- Dental Caries
- Being tested
- Povidone Iodine 5% Soln,Top,Kit, Probiotics, Placebo
- Keywords
- Dental Caries, Povidone Iodine, Probiotics
- Medical subject headings
- Dental Caries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Povidone Iodine 5% Soln,Top,KitDrug
Home use of Povidone Iodine administered by swabbing teeth; weekly for the 1st month, monthly thereafter.
ProbioticsDietary supplement
Home use of Povidone Iodine coupled with daily use of a probiotic.
PlaceboDrug
Placebo for the Povidone Iodine
| Study group | Role | What they receive |
|---|---|---|
| PI Alone | Experimental | This arm will be Povidone Iodine alone. Receives: Drug: Povidone Iodine 5% Soln,Top,Kit |
| PI plus Probiotics | Active comparator | This arm will determine if/how well probiotics improve the effect of the Povidone Iodine Receives: Drug: Povidone Iodine 5% Soln,Top,Kit; Dietary Supplement: Probiotics |
| Placebo | Placebo comparator | Placebo for the Povidone Iodine Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevention of Dental Caries
Change in the incidence of dental caries compared to placebo
Measured: Minimum 6 months; maximum 12 months
Secondary outcomes (1)
Microbiome
Change in the cariogenic potential of the plaque microbiome compared to the placebo.
Measured: Minimum 6 months; maximum 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2026
- Study start3 Aug 2026 (estimated)
- Primary completion31 Dec 2027 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (17)Papers the sponsor has linked to this study.
- Other trials for Dental CariesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 174 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Jeffrey A. Banas
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Jeffrey A. Banas, University of Iowa
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07741409
- Sponsor's protocol ID
- 202601408
- Other IDs
- N063700-G
- Status last verified
- Jul 2026
- First submitted
- 24 Jul 2026
- Last updated
- 3 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Confidentiality of participants
Publications
Milgrom P, Tut O, Rothen M, Mancl L, Gallen M, Tanzer JM. Addition of Povidone-Iodine to Fluoride Varnish for Dental Caries: A Randomized Clinical Trial. JDR Clin Trans Res. 2021 Apr;6(2):195-204. doi: 10.1177/2380084420922968. Epub 2020 May 21.
PubMed 32437626Lyashenko C, Herrman E, Irwin J, James A, Strauss S, Warner J, Khor B, Snow M, Ortiz S, Waid E, Nasry B, Chai J, Choong C, Palmer E, Kutsch K, Forsyth A, Choi D, Maier T, Machida CA. Adjunctive dental therapies in caries-active children: Shifting the cariogenic salivary microbiome from dysbiosis towards non-cariogenic health. Hum Microb J. 2020 Dec;18:100077. doi: 10.1016/j.humic.2020.100077. Epub 2020 Aug 31.
PubMed 34485763Li Y, Tanner A. Effect of Antimicrobial Interventions on the Oral Microbiota Associated with Early Childhood Caries. Pediatr Dent. 2015 May-Jun;37(3):226-44.
PubMed 26063552Muntean A, Mzoughi SM, Pacurar M, Candrea S, Inchingolo AD, Inchingolo AM, Ferrante L, Dipalma G, Inchingolo F, Palermo A, Bordea IR. Silver Diamine Fluoride in Pediatric Dentistry: Effectiveness in Preventing and Arresting Dental Caries-A Systematic Review. Children (Basel). 2024 Apr 22;11(4):499. doi: 10.3390/children11040499.
PubMed 38671716Papas AS, Vollmer WM, Gullion CM, Bader J, Laws R, Fellows J, Hollis JF, Maupome G, Singh ML, Snyder J, Blanchard P; PACS Collaborative Group. Efficacy of chlorhexidine varnish for the prevention of adult caries: a randomized trial. J Dent Res. 2012 Feb;91(2):150-5. doi: 10.1177/0022034511424154. Epub 2011 Dec 7.
PubMed 22156917Bokulich NA, Kaehler BD, Rideout JR, Dillon M, Bolyen E, Knight R, Huttley GA, Gregory Caporaso J. Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-feature-classifier plugin. Microbiome. 2018 May 17;6(1):90. doi: 10.1186/s40168-018-0470-z.
PubMed 29773078Sulyanto RM, Beall CJ, Berger MT, Goodell CP, Koo S, Candamo F, Dickson JR, Kang M, Ho SP, Ng MW, Hashmi SB, Leys EJ, Griffen AL. Silver diamine fluoride alters microbial communities in subsurface dentin. JADA Found Sci. 2022 Feb 8;1:100004. doi: 10.1016/j.jfscie.2021.100004. eCollection 2022.
PubMed 42238656Zhang JS, Chen Z, Chu CH, Yu OY. Effect of silver diamine fluoride upon the microbial community of carious lesions: A scoping review. J Dent. 2023 Jul;134:104554. doi: 10.1016/j.jdent.2023.104554. Epub 2023 May 21.
PubMed 37220834Weber-Gasparoni K, Kanellis MJ, Qian F. Iowa's public health-based infant oral health program: a decade of experience. J Dent Educ. 2010 Apr;74(4):363-71.
PubMed 20388808Ribeiro AA, Paster BJ. Dental caries and their microbiomes in children: what do we do now? J Oral Microbiol. 2023 Apr 10;15(1):2198433. doi: 10.1080/20002297.2023.2198433. eCollection 2023.
PubMed 37056224Mitwalli H, Mourao MDA, Dennison J, Yaman P, Paster BJ, Fontana M. Effect of Silver Diamine Fluoride Treatment on Microbial Profiles of Plaque Biofilms from Root/Cervical Caries Lesions. Caries Res. 2019;53(5):555-566. doi: 10.1159/000499578. Epub 2019 May 28.
PubMed 31137026Mei ML, Yan Z, Duangthip D, Niu JY, Yu OY, You M, Lo ECM, Chu CH. Effect of silver diamine fluoride on plaque microbiome in children. J Dent. 2020 Nov;102:103479. doi: 10.1016/j.jdent.2020.103479. Epub 2020 Sep 17.
PubMed 32950631Lopez L, Berkowitz R, Spiekerman C, Weinstein P. Topical antimicrobial therapy in the prevention of early childhood caries: a follow-up report. Pediatr Dent. 2002 May-Jun;24(3):204-6.
PubMed 12064491Kotha A, Vemulapalli A, Mandapati SR, Aryal S. Prevalence, Trends, and Severity of Early Childhood Caries in The United States: National Health and Nutritional Examination Survey Data 2013 to 2018. Pediatr Dent. 2022 Jul 15;44(4):261-268.
PubMed 35999681Frank S, Capriotti J, Brown SM, Tessema B. Povidone-Iodine Use in Sinonasal and Oral Cavities: A Review of Safety in the COVID-19 Era. Ear Nose Throat J. 2020 Nov;99(9):586-593. doi: 10.1177/0145561320932318. Epub 2020 Jun 10.
PubMed 32520599
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Povidone Iodine to Prevent Early Childhood Caries
- ClinicalTrials.gov ID
- NCT07741409
- Acronym / sponsor ID
- 202601408
- Conditions
- Dental Caries
- Keywords
- Dental Caries, Povidone Iodine, Probiotics
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 174 participants (estimated)
- Lead sponsor
- Jeffrey A. BanasUniversity, hospital or other
- Study start
- 3 Aug 2026 (estimated)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 3 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if Povidone Iodine works to prevent tooth decay and suppress the mouth germs responsible for tooth decay. The main questions it aims to answer are:
- How will home use of Povidone Iodine, as an adjunct treatment to standard dental care, reduce the incidence of tooth decay?
- How will home use of Povidone Iodine reduce the mouth germs responsible for tooth decay?
- If Povidone Iodine use is accompanied by probiotic use, will its effectiveness be even better than Povidone Iodine alone?
Participants will:
- Provide a plaque sample at the beginning of the study.
- Swab their children's teeth once a week for one month and then monthly thereafter. Some participants may be asked to use probiotic drops nightly after brushing their teeth.
- Keep a record of compliance.
- Return every 6 months for a dental exam and to provide a plaque sample. Keep a diary of their symptoms and the number of times they use a rescue inhaler
Detailed description
Dental 'caries' is the term used to describe dental decay or 'cavities'. Dental caries can occur at any age but lesions prior to a child's 6th birthday qualify as 'early childhood caries' (ECC) and possibly as 'severe' early childhood caries (SECC) if the onset and severity meet definitions put forth by the American Academy of Pediatric Dentistry. ECC and SECC can have several unfortunate downstream consequences: pain, infection, nutritional deficiencies, poorer concentration in school, and social/cosmetic/financial concerns. Recent epidemiologic trends in ECC/SECC, reported by Kotha et al. (2022) based on data from the National Health and Nutrition Examination Survey (NHANES), have found little change in prevalence over the span from 2013 to 2018 with approximately 20% of children experiencing ECC by age 3 years with over half that percentage categorized as having SECC. Thus, there remains a critical need to improve prevention and treatment strategies.
Many variables can affect the likelihood of developing dental decay but prominent among these are excess consumption of sugary foods and drinks, inadequate oral hygiene, and poor access to dental care and oral health educational resources. Ultimately, microbes on the surface of teeth convert dietary sugar to acid that dissolves enamel thereby initiating and advancing decay. Brushing regularly with fluoridated toothpaste helps suppress the microbial population which decreases the acid challenge while fluoride promotes remineralization of enamel. Seeing a dentist regularly can ensure that any decay that develops is treated at its earliest stages thereby saving teeth.
While prevention strategies work well for many individuals, for a multitude of potential reasons they may prove inadequate for others. In particular, children with poor access to professional care or who are disadvantaged in other respects frequently fail to realize the benefits of the current standard of care.
The objective of this investigation is to test the effectiveness of povidone iodine (PI) as a home-administered preventive or treatment for dental caries that, unlike other treatment options, addresses the underlying cause - dental plaque that has an overabundance of strong acid-producing bacterial species. This imbalance of strong acid producers is referred to as a 'dysbiosis'. We will also test whether combining PI with probiotics - living microbes that can be used to boost health - will have a greater benefit than PI alone in maintaining or restoring a healthy microbial composition to dental plaque. We are in a unique position to leverage our access to children at high risk for decay to test multiple integrated hypotheses that we predict will result in more effective home dental care, and significant reductions in the incidence and severity of dental decay that is longer lasting than is possible with the current standard of care.
Despite tremendous advances in understanding how particular microbes in dental plaque lead to tooth decay, prevention and treatment options remain non-specific - dedicated to plaque control rather than to replacing the offending microbes with health-related species (correcting the dysbiosis). This limitation results in the chronic presence of an elevated microbial risk that likely proves most consequential in individuals with limited access to professional care and suboptimal oral hygiene habits. Importantly, PI is unique among current standard of care options because there is evidence that it not only can prevent caries but that it also attacks the microbial offenders that drive caries development. The addition of fluoride to water supplies and oral health care products was a game-changer. Protection appears to be due to improving the enamel remineralization/demineralization balance rather than any antimicrobial activity despite in vitro evidence of selective toxicity against S. mutans.
Consequently, fluoride is excellent at caries prevention (when available/applied in adequate amounts and frequency) but does not improve a dysbiotic plaque microbiome. Chlorhexidine, sometimes prescribed for individuals with rampant caries, is considered the 'gold-standard' of anti-plaque agents but a large NIDCR-sponsored study (Papas et al., 2012) found no greater protection against caries than the use of fluoride alone.
Additionally, chlorhexidine use does not appear to remedy a cariogenic dysbiosis. Silver products have a long history in dental treatment and have generated renewed interest in recent years. The strong staining properties of silver, however, limit its application. The preponderance of evidence does not support a role for silver in improving a cariogenic microbial dysbiosis but further investigation is necessary.
Iodine, like silver, has long been recognized for its antiseptic/antimicrobial properties. Combining iodine with povidone improves water solubility. Evidence to date suggests that PI offers the greatest breadth of desirable properties but additional investigation is necessary in order to make a strong case for widespread adoption by clinicians. This proposal seeks to document the effectiveness of home use of PI for providing long-term reduction in caries risk by reducing the microbial dysbiosis within cariogenic dental plaque.
Hypothesis(es) and objective(s): We hypothesize that home use of PI will reduce the incidence and severity of dental decay in a high-risk population of children. Though not a substitute for proper oral hygiene such as brushing twice a day for two minutes each, its application is so quick that compliance is more likely than engaging in routine, effective oral hygiene and it would likely boost the effectiveness of imperfect oral hygiene practices. We further hypothesize that PI has selective toxicity for oral pathogens and its use would improve the microbial make-up of dental plaque thereby helping sustain beneficial effects. Finally, we hypothesize that this latter property of PI can be combined with probiotic administration to elevate the beneficial effect.
Study Protocol:
Patient Pool: The patient pool will be children of ages 1 to 3 years old who receive care
through the Infant Oral Health clinic that is part of the Iowa City Women, Infant, Children (WIC) Program in Iowa City. The University of Iowa Department of Pediatric Dentistry has an ongoing collaboration with the IC-WIC to provide oral health care and sees 16 to 24 children per week (Weber-Gasparoni et al., 2010). The children are typically from low-income families and all are at high risk for decay. We estimate that we could recruit 3 to 5 subjects/week. To estimate the number of subjects necessary to obtain statistically significant results, we extrapolated from the results of Lopez et al. (2002) who used 10% povidone iodine and an outcome measure of new caries. Based on the
differences between treatment and placebo groups, 126 subjects (42 Group 1, PI; 42 Group 2, PI + probiotics; and 42 Group 3, placebo) would give 80% power to determine a statistical difference in caries outcome with an alpha error of 0.05. To meet this number, we will enroll 174 subjects to account for an estimated 27% annual attrition.
Subjects will be randomly assigned to Groups 1, 2 or 3. However, if a subject consents to use PI but not probiotics, their assignment will be to either Group 1 or Group 3. We anticipate completing enrollment during year 1 of the study but have reserved 18 months to meet the recruitment goal. We also want to make clear that Group 3 will be the placebo group for the Group 1 iodine treatment. After considerable contemplation, we decided against including a strict placebo group for the probiotic administration. We considered having Group 3 use both the PI placebo and probiotic placebo but that would 'muddy' the analytical comparison with Group 1 (PI alone). Including another distinct placebo group would add considerable expense to the project that might not be justified if compliance with a daily regimen turned out to be low. As designed, we feel this project will yield strong data for the efficacy of home use of PI. The inclusion of a probiotic group has the potential to add significant insight into the mechanism by which PI exerts any observed benefit, or it may offer a lesson in the limits of compliance for any sort of daily oral health promoting regimen.
Enrollment and Visit Protocols: Pediatric Dental Residents will be the practitioners
treating the prospective participants. They will be calibrated with respect to caries scoring (ICDAS) prior to initiating the study. Once it is determined that the subjects satisfy the inclusion criteria (child of appropriate age; no imminent plans to relocate), they will follow an IRB-approved recruitment/enrollment protocol that will also determine
if any exclusion criteria (thyroid condition; antibiotic usage in the prior 3 months) apply. Once informed consent is obtained, the current caries status will be recorded and a pooled plaque sample will be taken using a sterile foam-tipped applicator (Puritan®) and swabbing all exposed tooth surfaces. The study coordinator will provide the practitioner with PI (Povi-One povidone iodine unit dose kit; Elevate Oral Care®), PI and probiotic drops (Prodentis by BioGaia), or placebo (colored tea for PI). The practitioner will apply the PI treatment onto the teeth of the participant and instruct them in home use. For participants given probiotic, verbal instructions will be provided to administer the drops once a day after brushing before bedtime. While this protocol precludes keeping practioners blinded with respect to the intervention, only the study coordinator will keep a record of the participants' group assignment so that practioners will not have access to group assignment records at follow-up appointments thereby minimizing the possibility of bias in subsequent caries evaluations. The PI protocol will be one application per week for one month and then once a month thereafter. Probiotic application will be daily. The concentration of the povidone iodine will be 5% and the maximum dose of probiotic will be 5 drops. The amount disbursed in an application and the frequency of application will be well within the safety margins for iodine exposure (Frank et al., 2020). Subjects will receive reminders ahead of a scheduled home application of PI via text message or communication method of choice to help ensure compliance. Subjects will also have the opportunity to reply to the messaging so that compliance can be tracked and/or keep a home diary of compliance and personal oral hygiene habits (How many times per day/week do the children brush? Themselves or by parents? Does the toothpaste contain fluoride?). At each 6-month follow-up
appointment, subjects will again have their caries status recorded and provide a pooled-plaque sample. They will also be asked questions related to use of antibiotics during the period between baseline and follow-up appointments. Maximal duration of participation for any subject will be 1 year.
Processing of Plaque Samples for Microbiome Analysis: Pooled plaque samples will be
collected as described above. The foam tip of the applicator will be broken off into 300ul RNAlater™ (Invitrogen) for transport to lab and isolation of DNA using the Qiagen DNeasy PowerLyzer PowerSoil Kit. The DNA that is recovered contains strands from all the microbes present in the sample. Technology allows the DNA to be sequenced and computational software is capable of analyzing the sequences and providing a breakdown of the proportional representation of the different types of microbes present. To accomplish this, the DNA samples will be sent to LC Sciences (Houston, TX) for the sequencing and microbial data analysis. [For those technically inclined, the 16S sequencing primers will target the V3 and V4 regions. The resulting 465bp amplicon will be sequenced on a NovaSeq platform with 250bp paired-end reads. Raw data files will be obtained in FASTQ format, overlapping sequences merged, screened for data quality and chimera filtered. The algorithm DADA2 will then be applied to generate representative sequences and construction of Amplicon Sequence Variant tables that will be the basis for analyses of diversity and differential abundance analyses.
Taxonomy will be assigned using the QIIME2 naïve bayes classifier (Bokulich et al., 2018) trained on the Human Oral Microbiome Database (HOMD) v15.23].
Previous studies have demonstrated that treatment with 10% PI can reduce salivary/plaque levels of the highly acidogenic bacterial species Streptococcus mutans (Amin et al., 2004; Simratvir et al., 2010) but further substantiation including effects on the totality of the oral microbial population are warranted. We recently completed a longitudinal study focusing on the microbial changes that preceded a diagnosis of ECC (unpublished data) and found that S. mutans appeared to be the main driver or major contributor in about three-quarters of the children. In the other 25% who developed caries, it appeared that non-mutans acidogenic species or the loss of base-producing species were the major drivers. Therefore, our microbiome analysis will focus on S. mutans as well as on changes in the representation of key genera that are health related (Neisseria, Haemophilus) or caries related (Actinomyces, Prevotella, Kingella, Candida).
Data Analyses: Our data analyses will focus on answering three main questions: 1) did
home use of PI reduce caries incidence and severity?; 2) did home use of PI reduce the presence in dental plaque of microbial species most associated with dental decay?; and 3) did a daily regimen of probiotics enhance the effectiveness of the PI treatments by further reducing caries incidence/severity and the presence of decay-associated microbes? To answer each of these questions, caries rates and microbial composition outcomes from Group 3 (placebo) will be compared with Groups 1 (PI) and 2 (PI + probiotic), individually and in combination. Outcomes from Groups 1 and 2 can also be compared directly. We expect to use ANOVA for statistical analysis but will consult with a biostatistician to ensure that all analyses are experimentally appropriate and valid.
The analyses described above will provide answers to our three main questions and directly address the hypotheses being tested. Our data on compliance will provide perspective for these outcomes. We anticipate that home use of PI is quick and simple enough to elicit good compliance. We are less sure of what to expect with the probiotic. On the one hand, administration (5 drops) is quicker than brushing one's teeth (though recommended use is after brushing). On the other hand, our study groups may not be particularly proficient in adhering to recommended oral hygiene practices. Overall, we expect the PI to be protective to a significant degree regardless of personal daily oral hygiene habits. However, we expect that the magnitude of protection will improve in direct proportion to the frequency of personal oral hygiene, including compliance of probiotic use.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| PI Alone | Experimental | Drug: Povidone Iodine 5% Soln,Top,KitThis arm will be Povidone Iodine alone. |
| PI plus Probiotics | Active comparator | Drug: Povidone Iodine 5% Soln,Top,Kit, Dietary Supplement: ProbioticsThis arm will determine if/how well probiotics improve the effect of the Povidone Iodine |
| Placebo | Placebo comparator | Drug: PlaceboPlacebo for the Povidone Iodine |
Who may qualify
- Ages
- 1 year to 3 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (2 listed)
- 1 to 3 years of age
- No plans to relocate in the next 12 months
Key exclusion criteria (2 listed)
- Thyroid condition
- Antibiotic usage in the prior 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Povidone Iodine 5% Soln,Top,KitHome use of Povidone Iodine administered by swabbing teeth; weekly for the 1st month, monthly thereafter. | Drug | PI Alone, PI plus Probiotics |
| ProbioticsHome use of Povidone Iodine coupled with daily use of a probiotic. | Dietary supplement | PI plus Probiotics |
| PlaceboPlacebo for the Povidone Iodine | Drug | Placebo |
Primary outcome
Prevention of Dental Caries
Time frame: Minimum 6 months; maximum 12 months
Change in the incidence of dental caries compared to placebo
1 secondary outcome
Microbiome
Time frame: Minimum 6 months; maximum 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2026.
- Background: PubMed 32437626Milgrom P, Tut O, Rothen M, Mancl L, Gallen M, Tanzer JM. Addition of Povidone-Iodine to Fluoride Varnish for Dental Caries: A Randomized Clinical Trial. JDR Clin Trans Res. 2021 Apr;6(2):195-204. doi: 10.1177/2380084420922968. Epub 2020 May 21.
- Background: PubMed 34485763Lyashenko C, Herrman E, Irwin J, James A, Strauss S, Warner J, Khor B, Snow M, Ortiz S, Waid E, Nasry B, Chai J, Choong C, Palmer E, Kutsch K, Forsyth A, Choi D, Maier T, Machida CA. Adjunctive dental therapies in caries-active children: Shifting the cariogenic salivary microbiome from dysbiosis towards non-cariogenic health. Hum Microb J. 2020 Dec;18:100077. doi: 10.1016/j.humic.2020.100077. Epub 2020 Aug 31.
- Background: PubMed 26063552Li Y, Tanner A. Effect of Antimicrobial Interventions on the Oral Microbiota Associated with Early Childhood Caries. Pediatr Dent. 2015 May-Jun;37(3):226-44.
- Background: PubMed 38671716Muntean A, Mzoughi SM, Pacurar M, Candrea S, Inchingolo AD, Inchingolo AM, Ferrante L, Dipalma G, Inchingolo F, Palermo A, Bordea IR. Silver Diamine Fluoride in Pediatric Dentistry: Effectiveness in Preventing and Arresting Dental Caries-A Systematic Review. Children (Basel). 2024 Apr 22;11(4):499. doi: 10.3390/children11040499.
- Background: PubMed 22156917Papas AS, Vollmer WM, Gullion CM, Bader J, Laws R, Fellows J, Hollis JF, Maupome G, Singh ML, Snyder J, Blanchard P; PACS Collaborative Group. Efficacy of chlorhexidine varnish for the prevention of adult caries: a randomized trial. J Dent Res. 2012 Feb;91(2):150-5. doi: 10.1177/0022034511424154. Epub 2011 Dec 7.
- Background: PubMed 29773078Bokulich NA, Kaehler BD, Rideout JR, Dillon M, Bolyen E, Knight R, Huttley GA, Gregory Caporaso J. Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-feature-classifier plugin. Microbiome. 2018 May 17;6(1):90. doi: 10.1186/s40168-018-0470-z.
- Background: PubMed 42238656Sulyanto RM, Beall CJ, Berger MT, Goodell CP, Koo S, Candamo F, Dickson JR, Kang M, Ho SP, Ng MW, Hashmi SB, Leys EJ, Griffen AL. Silver diamine fluoride alters microbial communities in subsurface dentin. JADA Found Sci. 2022 Feb 8;1:100004. doi: 10.1016/j.jfscie.2021.100004. eCollection 2022.
- Background: PubMed 37220834Zhang JS, Chen Z, Chu CH, Yu OY. Effect of silver diamine fluoride upon the microbial community of carious lesions: A scoping review. J Dent. 2023 Jul;134:104554. doi: 10.1016/j.jdent.2023.104554. Epub 2023 May 21.
- Background: PubMed 20388808Weber-Gasparoni K, Kanellis MJ, Qian F. Iowa's public health-based infant oral health program: a decade of experience. J Dent Educ. 2010 Apr;74(4):363-71.
- Background: PubMed 37056224Ribeiro AA, Paster BJ. Dental caries and their microbiomes in children: what do we do now? J Oral Microbiol. 2023 Apr 10;15(1):2198433. doi: 10.1080/20002297.2023.2198433. eCollection 2023.
- Background: PubMed 31137026Mitwalli H, Mourao MDA, Dennison J, Yaman P, Paster BJ, Fontana M. Effect of Silver Diamine Fluoride Treatment on Microbial Profiles of Plaque Biofilms from Root/Cervical Caries Lesions. Caries Res. 2019;53(5):555-566. doi: 10.1159/000499578. Epub 2019 May 28.
- Background: PubMed 32950631Mei ML, Yan Z, Duangthip D, Niu JY, Yu OY, You M, Lo ECM, Chu CH. Effect of silver diamine fluoride on plaque microbiome in children. J Dent. 2020 Nov;102:103479. doi: 10.1016/j.jdent.2020.103479. Epub 2020 Sep 17.
- Practitioner who used Povidone Iodine for caries preventionLink provided by the sponsor.
- Individual participant dataSharing planned: No. Confidentiality of participants
Related trials for Dental Caries
Not yet recruiting
Clinical and Radiographic Evaluation of Silver Diamine Fluoride Versus Light-Cured Silver Diamine Fluoride in Carious Primary Molars
Dental Caries
Not yet recruiting
Effect of Xylitol- Versus Erythritol-Sweetened Mints on Plaque ATP-Bioluminescence Readings
Dental Caries, Dental Plaque
Not yet recruiting
Clinical Performance of CAD/CAM Hard Hybrid Ceramic Inlays Versus Resin Composite Inlays in Vital Molars With Extensive Occluso-Proximal Cavities
Dental Caries, Cavity, Dental
Recruiting
Oral Health Intervention in Adult Primary Care
Dental Caries, Dry Mouth
Not yet recruitingObservational study
Artificial Intelligence Versus Clinical Examination in White Spot Lesions Detection, Identification, And Scoring
White Spot Lesion of Tooth
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Povidone Iodine 5% Soln,Top,Kit and Probiotics in people with Dental Caries, run by Jeffrey A. Banas at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jeffrey Banas, PHD (+1 319 335 9911, jeffrey-banas@uiowa.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevention of Dental Caries (time frame: Minimum 6 months; maximum 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07741409, which also lists 17 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2026.